Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

CIPLA Fact Sheet, CIPLA Financial Results - Equitymaster

Jan 21, 2022 | Updated on Jan 21, 2022

Check out CIPLA fact sheet and CIPLA financial results online at Equitymaster.

CIPLA Quarterly Results - Equitymaster

Jan 21, 2022 | Updated on Jan 21, 2022

Check out latest CIPLA Quarterly Results online at Equitymaster.

CIPLA Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Jan 21, 2022 | Updated on Jan 21, 2022

CIPLA: Get the latest CIPLA Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

5 Stocks to Watch Out for Amid the Omicron Outbreak

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Indian Pharma Companies Riding the Vaccination Wave

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Cipla Shares Tank Despite Strong Earnings

Aug 6, 2021

The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.

Cipla's New Covid-19 Drug to Be Sold at Rs 59,750 Per Dose

May 25, 2021

The first batch of Roche's antibody cocktail has been launched in India, with the second batch to be made available by mid-June.

Cipla's Q4 Update: Net Profit Surges 68%; Company to Pay Rs 5 Dividend

May 17, 2021

Here's a rundown on the latest quarterly results of Cipla.

Pharma: Big guns, big dreams!

Feb 13, 2006

Companies from the pharma sector posted mixed results in the recently concluded December quarter. Barring Ranbaxy, the other large-cap pharma companies showed a relatively better performance. We have included four large-caps for the purpose of analysis of the sector's performance during the December quarter. These include Ranbaxy, Dr. Reddy's, Sun Pharma and Cipla. Glaxo has been excluded as the company has yet to declare its results.

Cipla: Living upto expectations

Oct 26, 2004

Domestic pharma major, Cipla, declared its 2QFY05 and 1HFY05 results. The topline grew by 29% in the quarter led by a good performance in both formulation exports as well as in the domestic pharma market. The bottomline has grown by 38%, which was basically due to expansion of margins.

Cipla vs Peers

Aug 13, 2004

Cipla has seen a lot of activity over the past one month, and the stock has gained about 15% since July 2004. In the same period, the other two pharma giants, Dr Reddy's and Ranbaxy have gained only 3% and 6% respectively. So what has caught the investor's fancy with regard to Cipla? Let's find out.

Pharma: Global Vs local

Jun 10, 2004

There are two types of companies in the Indian pharma industry. While some are subsidiaries of global giants, others are home grown companies. Glaxo, Pfizer, Aventis and Novartis fall in the former category, while Ranbaxy, Cipla, Dr Reddy's, Wockhardt and Nicholas Piramal fall in the latter. Let's compare their business models and their performance.

A dose of Cipla

Mar 17, 2004

Cipla is one of the largest bulk drug and formulations manufacturer in the country. Ranked second in India by ORG in terms of retail pharmaceutical sales, the company has manufacturing facilities at Kurkumbh, Bangalore, Patalganga, Vikhroli (Mumbai) and Verna (Goa). All the bulk drug manufacturing facilities of the company have been approved by the US FDA and the formulation facilities have been approved by the Medicine Control Agency - UK, the Medicine Control Council - South Africa, the Therap

Cipla: Margins continue to slide

Oct 31, 2003

Cipla has announced its 2QFY04 results. Buoyed by a strong growth in the domestic as well as international markets, the company has reported a 23% growth in the topline. However, a sharp increase in material and staff cost has put pressure on its operating margins, thus resulting in a 6% drop in the bottomline. For 1HFY04, Cipla has reported an 18% growth in net profits and a marginal 2% growth in bottomline.

Cipla: Is the upswing justified?

Sep 5, 2003

Domestic pharma major, Cipla has seen a sharp rise in its stock price in the past one month. The stock price has gone up from Rs 806 on 1st Aug '03 to Rs 994 on 3rd Sep '03. Infact the stock had almost breached its 52-week high level during this period. But is this upsurge in price driven by fundamentals or is this just another speculative run that will end in the stock prices crashing as quickly as they gained. Let us find out!

WTO agreement: The fine print

Sep 2, 2003

Indian pharma stocks are having a dream run on the bourses in the past few weeks. Many companies like Cipla, Ranbaxy, Nicholas Piramal, Wockhardt, Aurobindo Pharma and Kopran are trading at their 52-week high levels. One of the major reasons for this upswing that is doing the rounds is the fact that the WTO members have finally agreed on a draft resolution regarding the licensing of life-saving drugs to least developed countries and its possible upside for the Indian companies. In this article,

Cipla: Margins under pressure

Aug 4, 2003

Domestic pharma major, Cipla announced its first quarter FY04 results recently. While the company has posted a 13% increase in the topline, a marginal drop in the operating efficiency has resulted in the company recording an 11% increase in the bottomline. Let us briefly evaluate the performance of the company during 1QFY04.

Cipla: Domestic market blues...

Apr 28, 2003

Domestic pharma major, Cipla Ltd, has posted disappointing March numbers. The company has reported a marginal 2% dip in income from operations, but net profits shrunk by over 24% during the quarter. The company's operating margins nearly halved to just over 12% in 4QFY03.

Cipla: 2QFY03 PAT up 22%

Oct 22, 2002

Cipla has reported 22% growth in net profits and 16% rise in topline for 2QFY03. The growth has been primarily on the back of healthy rise in export sales. Operating margins have registered a 270 basis points rise. However, compared to first quarter, YoY sales growth has declined.

Cipla: Omeprazole disappointment

Oct 14, 2002

In a big disappointment for Cipla, Andrx the US partner of the company has lost its patent challenge for generic Omeprazole (Prilosec). The US district court has ruled that Andrx infringes the original patent of AstraZeneca. Since Cipla was expected to supply a major part of Andrx’s raw material requirement for Omeprazole, market participants were expecting major revenues from this bulk exports.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS